{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:09:15Z","timestamp":1762092555353,"version":"build-2065373602"},"reference-count":50,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2023,7,3]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>The National Institute for Health and Care Excellence (NICE) guidelines present a synopsis of extensive internal evidence and technology reviews, with a particular focus on clinical efficacy and cost-effectiveness within the NHS in England. This approach has delivered a novel perspective on arrhythmia management, with important distinctions from other policymakers\u2019 recommendations. For example, when compared with the European Society of Cardiology (ESC) and the American Heart Association (AHA)\/Heart Rhythm Society (HRS)\/American College of Cardiology (ACC) guidelines on atrial fibrillation (AF), NICE advocates unique strategies regarding arrhythmia detection, stroke and bleeding risk stratification, and rhythm control (NICE CG 196). Likewise, for patients at risk of sudden cardiac death, NICE TA314 not only recommends device therapy based on New York Heart Association class and ECG findings, but also incorporates quality-adjusted life year data from analysis of key randomised controlled trials.<\/jats:p>\n               <jats:p>This review examines the NICE guidelines, together with those from the AHA\/HRS\/ACC and ESC, on the management of AF and ventricular arrhythmias and highlights the key common features and discrepancies between these important documents.<\/jats:p>","DOI":"10.1136\/heartjnl-2022-322122","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T13:20:37Z","timestamp":1690204837000},"page":"313-322","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Review of the National Institute for Health and Care Excellence guidelines on the management of atrial and ventricular arrhythmias"],"prefix":"10.1136","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9055-9267","authenticated-orcid":false,"given":"Pier D","family":"Lambiase","sequence":"first","affiliation":[{"name":"Cardiac Electrophysiology, St Bartholomew's Hospital, London, UK"},{"name":"Institute of Cardiovascular Sciences, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6177-2221","authenticated-orcid":false,"given":"Edd","family":"Maclean","sequence":"additional","affiliation":[{"name":"Cardiac Electrophysiology, St Bartholomew's Hospital, London, UK"},{"name":"Queen Mary University of London, William Harvey Research Institute, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"2025092006410501000_110.5.313.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.316340"},{"key":"2025092006410501000_110.5.313.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707855"},{"key":"2025092006410501000_110.5.313.3","doi-asserted-by":"crossref","unstructured":"January CT , Samuel Wann L , Calkins H , et al . AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology\/American heart Association task force on clinical practice guidelines and the heart R. Circulation 2019;140. doi:10.1161\/CIR.0000000000000719","DOI":"10.1161\/CIR.0000000000000665"},{"key":"2025092006410501000_110.5.313.4","doi-asserted-by":"crossref","unstructured":"January CT , Wann LS , Alpert JS , et al . AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol 2014. doi:10.1016\/j.jacc.2014.03.022","DOI":"10.1016\/j.jacc.2014.03.022"},{"key":"2025092006410501000_110.5.313.5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"2025092006410501000_110.5.313.6","unstructured":"National Institute for Health and Care Excellence . Atrial fibrillation: diagnosis and management. Clinical G; 2021."},{"key":"2025092006410501000_110.5.313.7","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.119.044126"},{"key":"2025092006410501000_110.5.313.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901183"},{"key":"2025092006410501000_110.5.313.9","unstructured":"The UK National Screening Committee . Adult screening programme: atrial fibrillation. n.d. Available: https\/\/view-health-screening-recommendations.service.gov.uk\/atrial-fibrillation\/"},{"key":"2025092006410501000_110.5.313.10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/europace\/euaa065","article-title":"European heart rhythm Association (EHRA)\/Heart rhythm society (HRS)\/Asia Pacific heart rhythm society (APHRS)\/Latin American heart rhythm society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population","volume":"22","author":"Nielsen","year":"2020","journal-title":"Europace"},{"key":"2025092006410501000_110.5.313.11","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1161\/CIRCULATIONAHA.120.053100","article-title":"Biomarker-based risk prediction with the ABC-AF scores in patients with atrial fibrillation not receiving oral anticoagulation","volume":"143","author":"Benz","year":"2021","journal-title":"Circulation"},{"key":"2025092006410501000_110.5.313.12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/ehjcvp\/pvac060","article-title":"Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: observations from the prospective EMIR registry","volume":"9","author":"Esteve-Pastor","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025092006410501000_110.5.313.13","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/ehjqcco\/qcab069","article-title":"Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF general long-term Registry","volume":"8","author":"Proietti","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2025092006410501000_110.5.313.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00741-8"},{"key":"2025092006410501000_110.5.313.15","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1055\/s-0038-1675400","article-title":"Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review","volume":"118","author":"Borre","year":"2018","journal-title":"Thromb Haemost"},{"key":"2025092006410501000_110.5.313.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"2025092006410501000_110.5.313.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.15192"},{"key":"2025092006410501000_110.5.313.18","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1161\/CIRCULATIONAHA.121.057063","article-title":"Amplatzer amulet left atrial appendage occluder versus watchman device for stroke prophylaxis (amulet IDE): a randomized, controlled trial","volume":"144","author":"Lakkireddy","year":"2021","journal-title":"Circulation"},{"key":"2025092006410501000_110.5.313.19","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.120.050117","article-title":"Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial","volume":"143","author":"Kar","year":"2021","journal-title":"Circulation"},{"key":"2025092006410501000_110.5.313.20","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2010.215335"},{"key":"2025092006410501000_110.5.313.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.08.041"},{"key":"2025092006410501000_110.5.313.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001337"},{"key":"2025092006410501000_110.5.313.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021328"},{"key":"2025092006410501000_110.5.313.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.07.046"},{"key":"2025092006410501000_110.5.313.25","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-012-6374-4"},{"key":"2025092006410501000_110.5.313.26","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-3013-303863"},{"key":"2025092006410501000_110.5.313.27","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/europace\/euab029","article-title":"Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with Paroxysmal atrial fibrillation","volume":"23","author":"Kuniss","year":"2021","journal-title":"Europace"},{"key":"2025092006410501000_110.5.313.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029980"},{"key":"2025092006410501000_110.5.313.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029554"},{"key":"2025092006410501000_110.5.313.30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10840-018-0425-0","article-title":"Catheter ablation versus conventional treatment of atrial fibrillation in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials","volume":"53","author":"Brice\u00f1o","year":"2018","journal-title":"J Interv Card Electrophysiol"},{"key":"2025092006410501000_110.5.313.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602014"},{"key":"2025092006410501000_110.5.313.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041489"},{"key":"2025092006410501000_110.5.313.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0901889"},{"key":"2025092006410501000_110.5.313.34","unstructured":"NICE . Implantable Cardioverter Defibrillators and cardiac Resynchronisation therapy for arrhythmias and heart failure; 2014."},{"key":"2025092006410501000_110.5.313.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.08.027"},{"key":"2025092006410501000_110.5.313.36","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"2025092006410501000_110.5.313.37","doi-asserted-by":"crossref","unstructured":"Al-Khatib SM , Stevenson WG , Ackerman MJ . AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation 2018;138. doi:10.1161\/CIR.0000000000000549","DOI":"10.1161\/CIR.0000000000000614"},{"key":"2025092006410501000_110.5.313.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608029"},{"key":"2025092006410501000_110.5.313.39","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jacep.2022.12.008","article-title":"Management of ventricular arrhythmias worldwide: comparison of the latest ESC, AHA\/ACC\/HRS, and CCS\/CHRS guidelines","volume":"9","author":"K\u00f6nemann","year":"2023","journal-title":"JACC Clin Electrophysiol"},{"key":"2025092006410501000_110.5.313.40","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jacep.2020.08.032","article-title":"A primary prevention clinical risk score model for patients with Brugada syndrome (BRUGADA-RISK)","volume":"7","author":"Honarbakhsh","year":"2021","journal-title":"JACC Clin Electrophysiol"},{"key":"2025092006410501000_110.5.313.41","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2018-313053"},{"key":"2025092006410501000_110.5.313.42","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1161\/CIRCULATIONAHA.122.059598","article-title":"Does timing of ventricular tachycardia ablation affect prognosis in patients with an Implantable cardioverter defibrillator? results from the multicenter randomized PARTITA trial","volume":"145","author":"Della Bella","year":"2022","journal-title":"Circulation"},{"key":"2025092006410501000_110.5.313.43","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.jacc.2022.01.050","article-title":"Substrate ablation vs antiarrhythmic drug therapy for symptomatic ventricular tachycardia","volume":"79","author":"Arenal","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025092006410501000_110.5.313.44","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1161\/CIRCULATIONAHA.122.060039","article-title":"First-line catheter ablation of monomorphic ventricular tachycardia in cardiomyopathy concurrent with defibrillator implantation: the PAUSE-SCD randomized trial","volume":"145","author":"Tung","year":"2022","journal-title":"Circulation"},{"key":"2025092006410501000_110.5.313.45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1513614","article-title":"Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs","volume":"375","author":"Sapp","year":"2016","journal-title":"N Engl J Med"},{"key":"2025092006410501000_110.5.313.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.06.040"},{"key":"2025092006410501000_110.5.313.47","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJMoa1915932","article-title":"Subcutaneous or transvenous defibrillator therapy","volume":"383","author":"Knops","year":"2020","journal-title":"N Engl J Med"},{"key":"2025092006410501000_110.5.313.48","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.hrthm.2017.05.016","article-title":"Subcutaneous Implantable Cardioverter-Defibrillator post-approval study: clinical characteristics and perioperative results","volume":"14","author":"Gold","year":"2017","journal-title":"Heart Rhythm"},{"key":"2025092006410501000_110.5.313.49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.120.048728","article-title":"Primary results from the understanding outcomes with the S-ICD in primary prevention patients with low ejection fraction (UNTOUCHED) trial","volume":"143","author":"Gold","year":"2021","journal-title":"Circulation"},{"key":"2025092006410501000_110.5.313.50","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ahj.2019.05.002","article-title":"Rationale and design of the PRAETORIAN-DFT trial: a prospective randomized comparative trial of subcutaneous Implantable Cardioverter-Defibrillator implantation with and without Defibrillation testing","volume":"214","author":"Quast","year":"2019","journal-title":"Am Heart J"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2022-322122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T13:41:17Z","timestamp":1758375677000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2022-322122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,2,12]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/heartjnl-2022-322122"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2022-322122","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"type":"print","value":"1355-6037"},{"type":"electronic","value":"1468-201X"}],"subject":[],"published":{"date-parts":[[2023,7,24]]}}}